hC Bioscience Appoints Martin Maier, Ph.D. To its Scientific Advisory Board; Brings Expertise in Therapeutic Nucleic Acid Development and Delivery

Cambridge, Massachusetts--(Newsfile Corp. - December 7, 2022) - hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board. Dr. Maier's background will bring, among other contributions, an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • hC Bioscience names Martin Maier, Ph.D., to its Scientific Advisory Board.
  • The company's SAB includes a group of experts spanning basic, translational, and clinical R&D.
  • Dr. Maier's background will bring an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/147096_figure1_550.jpg

Click image above to view full announcement.


About hC Bioscience, Inc.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Contacts:

Savannah Beaver
(617) 804-0366
savannah@reportablenews.com

Source: hC Bioscience

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/147096

info